NYSEHealth CareMedical - DevicesSnapshot 2026-08-31
Reading ZBH? Create a free portfolio, then add this holding for ongoing Reports and tracking. Track it in a free portfolio. No credit card.
Create your account →Intact: The reason to own it still holds.
Zimmer Biomet grows revenue about 3% to 4.5% in 2026. Adjusted EPS is raised to about $8.47 per share. The company plans to repurchase up to $1 billion of shares in 2026. Recent acquisitions expand product offerings and support growth.
Growth faces headwinds that may slow revenue below 3%. Management changes and new debt raise uncertainty. Profit margins and EPS could weaken if execution falters.
The stock price is about 25% below our fair value near $120. Analysts expect roughly 3% revenue growth. Our view is slightly more optimistic on growth and EPS than consensus.
Breaks if: Adjusted EPS falls below $8.40 in FY26
Breaks if: Repurchases fall significantly short of $1 billion in FY26
Breaks if: YoY revenue growth falls below 2.5% in FY26
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
ZBH represents a durable compounder in the healthcare sector. The current thesis is intact, supported by strong recent financial performance and management priorities focused on share repurchases and earnings growth.
The market appears to have a neutral valuation for ZBH, with expectations slightly below peers. This suggests that while the company is viewed as justified in its current position, there is room for improvement compared to its industry counterparts.
ZBH's fundamentals are likely to remain strong, given its robust earnings quality and on-track management priorities. However, there is a moderate risk due to potential guidance cuts and the overall economic environment.
The long-term thesis hinges on the performance of sector bellwethers and the broader economic outlook. Key triggers include the potential for guidance cuts and the impact of job market trends on healthcare stocks.
The most important moves since the prior daily snapshot.
Mixed, the news cuts both ways. The latest earnings beat and raised guidance support growth objectives. However, growth concerns may hinder an increase in EPS guidance for 2026.
as of 2026-08-31
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Target full-year 2026 revenue growth in the range of approximately 2.5% to 4.9%, including organic and constant currency growth.
Stated as a priority in 3 of last 3 quarters. Revenue grew from $8.232 billion in 2025 to an estimated $8.467 billion in 2026, reflecting 3.9% to 4.9% growth guidance. Actual reported revenue in 2026-Q1 and Q2 showed growth consistent with this guidance, indicating delivery on this priority.
“Updated Guidance 2026 Reported Revenue Change 3.9% - 4.9%”
“2026 Reported Revenue Change 2.5% - 4.5%”
“The Company is providing the following full-year 2026 financial guidance: 2026 Reported Revenue Change 2.5% - 4.5%”
In the next 1 to 3 years, ZBH's performance will depend on its ability to navigate economic challenges while maintaining its growth trajectory. Not investment advice.
